Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
bioAffinity Technologies, Inc. ( (BIAF) ) just unveiled an announcement.
On November 5, 2025, bioAffinity Technologies announced significant growth in the volume of their CyPath® Lung tests, with October’s test volume showing a 111% increase over the 2025 monthly average. This growth reflects the increasing recognition of the test’s clinical value by physicians and the success of the company’s outreach efforts to healthcare providers. The steady adoption of CyPath® Lung is seen as a step towards changing the standard of care in early lung cancer detection.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.
The overall stock score is heavily influenced by the company’s weak financial performance and negative valuation metrics. Technical analysis also indicates bearish trends, further impacting the score. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage lung cancer and other lung diseases. Their primary product, CyPath® Lung, is a noninvasive test that has demonstrated high sensitivity, specificity, and accuracy in detecting early-stage lung cancer. The test is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Average Trading Volume: 2,818,390
Technical Sentiment Signal: Sell
Current Market Cap: $9.4M
For detailed information about BIAF stock, go to TipRanks’ Stock Analysis page.